This is the authors' abstract. We don't add key points for this paper.
The pharmacokinetics, pharmacodynamics, and platelet binding of 7E3, an anti-glycoprotein IIb/IIIa (GPIIb/IIIa) monoclonal antibody, were studied in the rat in an attempt to develop a quantitative animal model of immune thrombocytopenia (ITP). 7E3, a murine IgG₁ antibody developed against human GPIIb/IIIa, demonstrated cross-reactivity with rat platelets by flow cytometry and via enzyme-linked immunosorbent assay. The apparent affinity (KA) of 7E3-rat platelet binding was 1.2 ± 0.2 × 10⁷ M⁻¹, with 3.3 ± 0.3 × 10⁴ binding sites per platelet. Following intravenous 7E3 administration (0.8, 4, and 8 mg/kg), plasma concentrations declined in a bi-exponential manner, with a terminal half-life of 61 ± 5 h and a steady-state volume of distribution of 62 ± 15 ml/kg. Clearance was dose-dependent, with values ranging from 0.64 ± 0.08 ml/h/kg (8 mg/kg) to 1.01 ± 0.08 ml/h/kg (0.8 mg/kg). 7E3 induced a reproducible, severe thrombocytopenia in rats and extended bleeding in a manner consistent with human ITP. Nadir platelet counts were 79 ± 33, 25 ± 6, and 17 ± 2 × 10⁶/ml, for 7E3 doses of 0.8, 4, and 8 mg/kg, respectively. Bleeding times after a 10-mm tail incision ranged from 5 ± 3 min in control animals to 15 ± 0 min (the maximum allowed time in this study) in animals receiving 8 mg/kg. Blood volumes lost during bleeding experiments ranged from 30 ± 24 μl (control) to 349 ± 358 μl (8 mg/kg). A reproducible, quantitative rat model of ITP has been created; this model is expected to facilitate the evaluation of new treatments for this disease.
Answers are grounded in this paper and cite their sources.
May inform preclinical ITP modeling; leaves open human translation and clinical relevance.
No takes yet. Share an insight, caveat, or question.
Smith et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: